Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNZ-2591 in Healthy Volunteers
NCT04379869Phase 1Completed
- Sponsor
- Neuren Pharmaceuticals Limited
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNZ-2591 in Angelman syndrome (AS), Phelan-McDermid syndrome (PMS), Pitt-Hopkins syndrome (PTHS) and 1 more (4 cohorts), sponsored by Neuren Pharmaceuticals Limited. Primary endpoint: Safety and Tolerability measured through Adverse Events /Serious Adverse Events at 25 days. Started May 2020; status: completed.
02
Drugs
NNZ-2591
03
Conditions
Angelman syndrome (AS)Phelan-McDermid syndrome (PMS)Pitt-Hopkins syndrome (PTHS)Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT04379869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379869.